Skip to main content
Top
Published in: Supportive Care in Cancer 12/2019

01-12-2019 | Nausea | Original Article

Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy

Authors: Nirosha Mahendraratnam, Joel F. Farley, Ethan Basch, Amber Proctor, Stephanie B. Wheeler, Stacie B. Dusetzina

Published in: Supportive Care in Cancer | Issue 12/2019

Login to get access

Abstract

Background

Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA.

Methods

Our study population was adult patients under the age of 65 with cancer initiating intravenous HEC between 2013 and 2015 with employer-sponsored insurance in the IBM Watson/Truven MarketScan Commercial Claims database (N = 31,923). Descriptive statistics were used to explain antiemetic prescribing patterns, including antiemetic underuse. Modified Poisson regression was used to identify factors associated with antiemetic underuse.

Results

Among individuals initiating HEC, 49% underused guideline-concordant antiemetics. Most classified as under-using lacked an NK1 fill. While dexamethasone and 5HT3A uptake was over 80%, olanzapine use was minimal. Having lower generosity for prescription and medical benefits (paying more versus less than 20% out-of-pocket) increased the underuse risk by 3% and 4% (RR,1.03; 95% CI,1.01–1.05; P = 0.01 and RR,1.04; CI, 1.00–1.09; P = 0.03), respectively. Additionally, compared to receiving chemotherapy in the physician office setting, patients were at a 28% (RR, 1.28; 95% CI, 1.25–1.30; P < 0.0001) higher underuse risk in the outpatient hospital setting.

Conclusion

Antiemetic underuse is high in patients initiating HEC, potentially leading to avoidable CINV events. We found that insurance generosity has a minimal effect on antiemetic guideline concordance in this population, suggesting discordance may be the result of site of care as well as gaps in provider knowledge or accountability.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103(2):117–128CrossRef Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103(2):117–128CrossRef
3.
go back to reference Feinberg BA, Lang J, Grzegorczyk J et al (2012) Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers. J Oncol Pract 8(3 Suppl):e38s–e43sCrossRef Feinberg BA, Lang J, Grzegorczyk J et al (2012) Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers. J Oncol Pract 8(3 Suppl):e38s–e43sCrossRef
4.
go back to reference Newcomer LN, Gould B, Page RD, Donelan SA, Perkins M (2014) Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract 10(5):322–326CrossRef Newcomer LN, Gould B, Page RD, Donelan SA, Perkins M (2014) Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract 10(5):322–326CrossRef
5.
go back to reference Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13–36CrossRef Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13–36CrossRef
6.
go back to reference Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Supporti Care Cancer 15(5):497–503CrossRef Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Supporti Care Cancer 15(5):497–503CrossRef
7.
go back to reference Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307–313CrossRef Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307–313CrossRef
8.
go back to reference Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19(1):131–140CrossRef Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19(1):131–140CrossRef
9.
go back to reference Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 110(3):678–685CrossRef Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 110(3):678–685CrossRef
10.
go back to reference Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–851CrossRef Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–851CrossRef
11.
go back to reference Craver C, Gayle J, Balu S, Buchner D (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14(1):87–98CrossRef Craver C, Gayle J, Balu S, Buchner D (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14(1):87–98CrossRef
12.
go back to reference Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15(3):526–536CrossRef Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15(3):526–536CrossRef
13.
go back to reference Lordick F, Ehlken B, Ihbe-Heffinger A et al (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 43(2):299–307CrossRef Lordick F, Ehlken B, Ihbe-Heffinger A et al (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 43(2):299–307CrossRef
14.
go back to reference Viale PH, Grande C, Moore S (2012) Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 16(4):E133–E141CrossRef Viale PH, Grande C, Moore S (2012) Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 16(4):E133–E141CrossRef
15.
go back to reference Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12(9):1143–1150CrossRef Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12(9):1143–1150CrossRef
16.
go back to reference Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367CrossRef Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367CrossRef
18.
go back to reference Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261CrossRef Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261CrossRef
19.
go back to reference National Comprehensive Cancer Network (2017) NCCN clinical practice guidelines in oncology: antiemesis V1. 2017 National Comprehensive Cancer Network (2017) NCCN clinical practice guidelines in oncology: antiemesis V1. 2017
20.
go back to reference Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRef Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRef
21.
go back to reference Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10(1):68–74CrossRef Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10(1):68–74CrossRef
22.
go back to reference Chavez-MacGregor M, He W, Zhao H et al (2015) Antiemesis prophylaxis among breast cancer (BC) patients receiving anthracyline-based chemotherapy: a population-based study. 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology International Symposium on Supportive Care in Cancer; June 25–27, 2015, Copenhagen, Denmark Chavez-MacGregor M, He W, Zhao H et al (2015) Antiemesis prophylaxis among breast cancer (BC) patients receiving anthracyline-based chemotherapy: a population-based study. 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology International Symposium on Supportive Care in Cancer; June 25–27, 2015, Copenhagen, Denmark
23.
go back to reference Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB (2016) Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Res Treat 156(2):351–359CrossRef Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB (2016) Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Res Treat 156(2):351–359CrossRef
24.
go back to reference Rogers MP, Blackburn L (2010) Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Clin J Oncol Nurs 14(4):500–504CrossRef Rogers MP, Blackburn L (2010) Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Clin J Oncol Nurs 14(4):500–504CrossRef
26.
go back to reference National Comprehensive Cancer Network (2015) Clinical practice guidelines in oncology: antiemesis (Version 2.2015) National Comprehensive Cancer Network (2015) Clinical practice guidelines in oncology: antiemesis (Version 2.2015)
27.
go back to reference Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198CrossRef Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198CrossRef
28.
go back to reference Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381–386CrossRef Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical Oncology (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381–386CrossRef
33.
go back to reference Zou G (2004) A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRef Zou G (2004) A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRef
34.
go back to reference Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134–142CrossRef Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134–142CrossRef
35.
go back to reference Food and Drug Administration Modernization Act of 1997, 21 U.S.C. (1997) Food and Drug Administration Modernization Act of 1997, 21 U.S.C. (1997)
36.
go back to reference Fonte C, Fatigoni S, Roila F (2015) A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol 95(2):214–221CrossRef Fonte C, Fatigoni S, Roila F (2015) A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol 95(2):214–221CrossRef
37.
go back to reference Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRef Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRef
38.
go back to reference Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147CrossRef Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147CrossRef
39.
go back to reference Bach PB, Jain RH (2017) Physician’s office and hospital outpatient setting in oncology: it’s about prices, not use. J Oncol Pract 13(1):4–5CrossRef Bach PB, Jain RH (2017) Physician’s office and hospital outpatient setting in oncology: it’s about prices, not use. J Oncol Pract 13(1):4–5CrossRef
40.
go back to reference Malin JL, Weeks JC, Potosky AL, Hornbrook MC, Keating NL (2013) Medical oncologists’ perceptions of financial incentives in cancer care. J Clin Oncol 31(5):530–535CrossRef Malin JL, Weeks JC, Potosky AL, Hornbrook MC, Keating NL (2013) Medical oncologists’ perceptions of financial incentives in cancer care. J Clin Oncol 31(5):530–535CrossRef
41.
go back to reference IQVIA (SK&A) (2017) Commercial Access to Physicians: Medical Industry Sales Reps Accessibility to U.S. Physicians. SK&A IQVIA (SK&A) (2017) Commercial Access to Physicians: Medical Industry Sales Reps Accessibility to U.S. Physicians. SK&A
42.
go back to reference Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24(5):2381–2392CrossRef Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24(5):2381–2392CrossRef
43.
go back to reference Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188–195CrossRef Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188–195CrossRef
Metadata
Title
Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy
Authors
Nirosha Mahendraratnam
Joel F. Farley
Ethan Basch
Amber Proctor
Stephanie B. Wheeler
Stacie B. Dusetzina
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04730-3

Other articles of this Issue 12/2019

Supportive Care in Cancer 12/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine